Itraconazole decreases renal clearance of digoxin

被引:120
作者
Jalava, KM
Partanen, J
Neuvonen, PJ
机构
[1] UNIV HELSINKI,DEPT MED,DIV CARDIOL,FIN-00290 HELSINKI,FINLAND
[2] UNIV HELSINKI,CENT HOSP,HELSINKI,FINLAND
关键词
itraconazole; digoxin; interaction; pharmacokinetics; clearance;
D O I
10.1097/00007691-199712000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Itraconazole strongly interacts with some drugs metabolized by cytochrome P450 3A4, for example, felodipine and lovastatin, by inhibiting their metabolism. A concomitant use of itraconazole increases the serum concentrations of digoxin, although digoxin is excreted mainly unchanged in urine. To reveal the mechanism of the itraconazole-digoxin interaction, the effect of itraconazole on the serum concentrations and urinary excretion of digoxin was studied. Ten healthy volunteers in a double-blind, randomized, two-phase crossover study received either 200 mg itraconazole or placebo orally once a day for 5 days. On day 3, each volunteer ingested a single 0.5-mg oral dose of digoxin. The serum concentrations of digoxin and its excretion into urine as well as plasma concentrations of itraconazole were determined up to 72 hours after dosing. The mean area under the serum digoxin concentration-time curve, AUC (0-72), was similar to 50% higher (P < 0.001) during the itraconazole phase than during the placebo phase. In addition, the renal clearance of digoxin decreased about 20% (P < 0.01) by itraconazole. The increases in digoxin C-max,, and T-1/2, by itraconazole were not statistically significant. The decreased renal clearance of digoxin during the itraconazole phase partially explains increased concentrations of digoxin during their concomitant use and may be caused by the inhibition of P-glycoprotein-mediated digoxin secretion in the renal tubular cells.
引用
收藏
页码:609 / 613
页数:5
相关论文
共 29 条
[1]  
*ABB LAB, 1993, TDXFLX TDX ASS MAN, V1
[2]   DIGOXIN-ITRACONAZOLE INTERACTION [J].
ALDERMAN, CP ;
JERSMANN, HPA .
MEDICAL JOURNAL OF AUSTRALIA, 1993, 159 (11-12) :838-839
[3]   DETERMINATION OF ITRACONAZOLE IN SERUM WITH HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE DETECTION [J].
ALLENMARK, S ;
EDEBO, A ;
LINDGREN, K .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 532 (01) :203-206
[4]  
BERNDT A, 1996, J CLIN PHARMACOL, V36, P848
[5]  
CALDWELL JH, 1976, CLIN PHARMACOL THER, V19, P410
[6]   INFLUENCE OF GASTRIC-ACIDITY ON THE BIOAVAILABILITY OF DIGOXIN [J].
COHEN, AF ;
KROON, R ;
SCHOEMAKER, R ;
HOOGKAMER, H ;
VANVLIET, A .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (07) :540-545
[7]   THE MDR1 GENE-PRODUCT, P-GLYCOPROTEIN, MEDIATES THE TRANSPORT OF THE CARDIAC GLYCOSIDE, DIGOXIN [J].
DELANNOY, IAM ;
SILVERMAN, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 189 (01) :551-557
[8]   CYCLOSPORINE AND QUINIDINE INHIBITION OF RENAL DIGOXIN EXCRETION - EVIDENCE FOR LUMINAL SECRETION OF DIGOXIN [J].
DELANNOY, IAM ;
KOREN, G ;
KLEIN, J ;
CHARUK, J ;
SILVERMAN, M .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 263 (04) :F613-F622
[9]   EVALUATION AND COMPARISON OF THE TDXII, STRATUS, AND OPUS DIGOXIN ASSAYS [J].
DODDS, HM ;
NORRIS, RLG ;
JOHNSON, AG ;
POND, SM .
THERAPEUTIC DRUG MONITORING, 1995, 17 (01) :68-74
[10]  
DOLLERY C, 1991, THERAPEUTIC DRUGS, V1, pD125